secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2026-09-18T20:05:35+00:00
Accession:  0001104659-26-108935
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio faces Nasdaq delisting over bid price; plans hearing and reverse split
-------------------------------------------------------------------------------

- Nasdaq notified TELA Bio on 9/15/26 it is subject to delisting for failing $1.00 minimum bid price rule.
- Company intends to request a Nasdaq Hearings Panel hearing, which will stay any suspension pending outcome.
- Filed proxy for reverse stock split (1-for-5 to 1-for-15) to regain bid price compliance; special meeting 10/8/26.
- No assurance stockholders approve reverse split; delisting risk persists if not approved or price not sustained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926108935/0001104659-26-108935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465926108935/tm2625586d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-108935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer